Tarsus Pharmaceuticals (TARS) EBT Margin (2021 - 2026)

Tarsus Pharmaceuticals' EBT Margin history runs 6 years deep, the most recent figure standing at 2.79% for Q1 2026.

• In Q1 2026, EBT Margin rose 2917.0% year-over-year to 2.79%; the TTM figure through Mar 2026 stood at 8.16% (up 3588.0% YoY), while the FY2025 annual figure was 14.26%, up 4890.0% from the prior year.
• EBT Margin was 2.79% for Q1 2026 at Tarsus Pharmaceuticals, up from 4.11% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 2.79% in Q1 2026 to a low of 3680.33% in Q1 2022.
• Historically, EBT Margin has averaged 503.4% across 5 years, with a median of 48.81% in 2024.
• Biggest YoY gain for EBT Margin was 413475 bps in 2022; the steepest drop was 371241 bps in 2022.
• A 5-year view of EBT Margin shows it stood at 136.26% in 2022, then tumbled by 138 bps to 324.72% in 2023, then jumped by 89 bps to 34.76% in 2024, then soared by 88 bps to 4.11% in 2025, then surged by 32 bps to 2.79% in 2026.
• The last three EBT Margin figures came in at 2.79% (Q1 2026), 4.11% (Q4 2025), and 10.69% (Q3 2025), per Business Quant data.